JPMorgan upgraded Allogene Therapeutics (ALLO) to Neutral from Underweight without a price target The firm cites valuation for the upgrade with the shares down 50% from the one-year peak since Monday’s ALPHA3 update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics Prices Large Common Stock Offering
- Allogene Therapeutics price target raised to $10 from $6 at Jefferies
- Unusually active option classes on open April 15th
- Allogene Therapeutics 87.5M share Spot Secondary priced at $2.00
- Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein